Aberrant transcription in prostate cancer is not driven solely by AR activity but through the collaborative action of AR enhancers like those of HOXB13 and FOXA1 genes, which modify chromatin structure to facilitate AR and other factors in accessing cancer-specific binding sites. This evidence concerns the gene AR and prostate carcinoma.